Replimune Group Quarterly Balance Sheet
NASDAQ: REPLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Replimune Group financial position
As of Sep 30, 2026, Replimune Group reported total assets of $373.9 million, down 4.0% from a year earlier against total liabilities of $169.2 million. Shareholders' equity stood at $204.8 million, or 54.8% of assets. The company held $307.8 million in cash and equivalents against $99.8 million of debt, a net cash position of $208.1 million.
The current ratio (current assets divided by current liabilities) was 7.11, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.49.
Summary generated from market data by MetaCap's automated system. Methodology
Replimune Group balance sheet (quarterly)
| Quarter (USD) | Q2 20272026-09-30 | Q1 20272026-06-30 | Q4 20262026-03-31 | Q3 20262025-12-31 | Q2 20262025-09-30 | Q1 20262025-06-30 | Q4 20252025-03-31 | Q3 20252024-12-31 | Q2 20252024-09-30 | Q1 20252024-06-30 | Q4 20242024-03-31 | Q3 20242023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 307.83M | 185.36M | 209.02M | 122.95M | 102.30M | 97.37M | 111.12M | 172.25M | 113.49M | 151.66M | 74.46M | 97.67M |
| Short-Term Investments | 0 | 9.97M | 59.87M | 146.19M | 221.35M | 305.97M | 372.69M | 364.29M | 318.56M | 317.47M | 346.21M | 368.68M |
| Inventory | 9.87M | — | 0 | — | — | — | — | — | — | — | — | — |
| Total Current Assets | 324.04M | 200.81M | 279.12M | 280.35M | 333.75M | 413.37M | 495.88M | 547.58M | 442.63M | 480.32M | 433.67M | 479.16M |
| Property, Plant & Equipment | 10.70M | 11.86M | 12.97M | 13.85M | 14.71M | 14.68M | 13.74M | 13.62M | 12.59M | 11.40M | 10.48M | 9.47M |
| Total Assets | 373.94M | 252.45M | 332.39M | 333.59M | 389.45M | 469.51M | 551.33M | 603.63M | 498.20M | 534.97M | 487.72M | 532.93M |
| Accounts Payable | 5.96M | 4.26M | 6.67M | 5.65M | 6.40M | 15.48M | 12.46M | 7.19M | 8.41M | 864.00K | 2.58M | 3.90M |
| Total Current Liabilities | 45.55M | 38.41M | 58.23M | 50.09M | 52.90M | 59.56M | 62.36M | 47.89M | 43.79M | 35.68M | 40.44M | 38.65M |
| Long-Term Debt | 99.77M | 84.11M | 83.31M | 47.63M | 47.21M | 46.79M | 46.38M | 45.96M | 45.57M | 45.19M | 44.81M | 44.43M |
| Total Liabilities | 169.16M | 146.80M | 166.23M | 123.05M | 126.11M | 132.79M | 135.49M | 121.25M | 116.74M | 108.51M | 113.21M | 111.39M |
| Shareholders' Equity | 204.78M | 105.64M | 166.16M | 210.54M | 263.34M | 336.71M | 415.84M | 482.37M | 381.46M | 426.45M | 374.51M | 421.54M |
| Retained Earnings | -1.39B | -1.33B | -1.26B | -1.19B | -1.12B | -1.04B | -948.58M | -874.45M | -808.11M | -755.05M | -701.28M | -646.21M |
| Total Debt | 99.77M | 84.11M | 83.31M | 47.63M | 47.21M | 46.79M | 46.38M | 45.96M | 45.57M | 45.19M | 44.81M | 44.43M |
| Net Cash (Debt) | 208.07M | 111.21M | 185.58M | 221.51M | 276.44M | 356.55M | 437.43M | 490.58M | 386.49M | 423.93M | 375.86M | 421.92M |
| Shares Outstanding | 94.81M | 83.98M | 82.72M | 79.63M | 78.40M | 77.81M | 77.09M | 77.01M | 68.39M | 68.31M | 61.42M | 61.39M |
This table shows 12 quarterly periods of Replimune Group's balance sheet, from Q2 2027 back to Q3 2024, across 15 line items including cash & equivalents, short-term investments, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow REPL's reporting calendar. What is a balance sheet?